The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Guidelines for preclinical animal research in ALS/MND: A consensus meeting
Open accessAbstract
The development of therapeutics for ALS/MND is largely based on work in experimental animals carrying human SOD mutations. However, translation of apparent therapeutic successes from in vivo to the human disease has proven difficult and a considerable amount of financial resources has been apparently wasted. Standard operating procedures (SOPs) for preclinical animal research in ALS/MND are urgently required. Such SOPs will help to establish SOPs for translational research for other neurological diseases within the next few years. To identify the challenges and to improve the research methodology, the European ALS/MND group held a meeting in 2006 and published guidelines in 2007 (1). A second international conference to improve the guidelines was held in 2009. These second and improved guidelines are dedicated to the memory of Sean F. Scott.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E., et al. (2008) · Science · doi:10.1126/science.1154584 · Cited by 2,630
Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6
Vance, C., Rogelj, B., Hortobágyi, T., De Vos, K. J., Nishimura, A. L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P., et al. (2009) · Science · doi:10.1126/science.1165942 · Cited by 2,564
Mutations in the FUS/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis
Kwiatkowski, T. J., Bosco, D. A., LeClerc, A. L., Tamrazian, E., Vanderburg, C. R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E. J., Munsat, T., et al. (2009) · Science · doi:10.1126/science.1166066 · Cited by 2,553
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
Kabashi, E., Valdmanis, P. N., Dion, P., Spiegelman, D., McConkey, B. J., Velde, C. V., Bouchard, J.-P., Lacomblez, L., Pochigaeva, K., Salachas, F., et al. (2008) · Nature Genetics · doi:10.1038/ng.132 · Cited by 1,544
Self-citationWong, P. C., Pardo, C. A., Borchelt, D. R., Lee, M. K., Copeland, N. G., Jenkins, N. A., Sisodia, S. S., Cleveland, D. W., & Price, D. L. (1995) · Neuron · doi:10.1016/0896-6273(95)90259-7 · Cited by 1,445
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V, Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,301
Rethinking ALS: The FUS about TDP-43
Lagier-Tourenne, C., & Cleveland, D. W. (2009) · Cell · doi:10.1016/j.cell.2009.03.006 · Cited by 588
Lithium delays progression of amyotrophic lateral sclerosis
Fornai, F., Longone, P., Cafaro, L., Kastsiuchenka, O., Ferrucci, M., Manca, M. L., Lazzeri, G., Spalloni, A., Bellio, N., Lenzi, P., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708022105 · Cited by 550
Cited by
A call for transparent reporting to optimize the predictive value of preclinical research
Landis, S. C., Amara, S. G., Asadullah, K., Austin, C. P., Blumenstein, R., Bradley, E. W., Crystal, R. G., Darnell, R. B., Ferrante, R. J., Fillit, H., et al. (2012) · Nature · doi:10.1038/nature11556 · Cited by 1,196
Preclinical research: Make mouse studies work
Perrin, S. (2014) · Nature · doi:10.1038/507423a · Cited by 668
Animal models of neurodegenerative diseases
Dawson, T. M., Golde, T. E., & Lagier-Tourenne, C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0236-8 · Cited by 576
Controversies and priorities in amyotrophic lateral sclerosis
Turner, M. R., Hardiman, O., Benatar, M., Brooks, B. R., Chio, A., de Carvalho, M., Ince, P. G., Lin, C., Miller, R. G., Mitsumoto, H., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70036-x · Cited by 541
Self-citationMead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00612-2 · Cited by 505
Self-citationJucker, M. (2010) · Nature Medicine · doi:10.1038/nm.2224 · Cited by 401
Risk of bias in reports of in vivo research: a focus for improvement
Macleod, M. R., Lawson McLean, A., Kyriakopoulou, A., Serghiou, S., de Wilde, A., Sherratt, N., Hirst, T., Hemblade, R., Bahor, Z., Nunes-Fonseca, C., et al. (2015) · PLOS Biology · doi:10.1371/journal.pbio.1002273 · Cited by 358
Castillo, K., Nassif, M., Valenzuela, V., Rojas, F., Matus, S., Mercado, G., Court, F. A., van Zundert, B., & Hetz, C. (2013) · Autophagy · doi:10.4161/auto.25188 · Cited by 340
Henderson, V. C., Kimmelman, J., Fergusson, D., Grimshaw, J. M., & Hackam, D. G. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001489 · Cited by 302
Mitsumoto, H., Brooks, B. R., & Silani, V. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70129-2 · Cited by 289
AP-HP, H. D. L. P.-S., & Gordon, P. (2013) · Aging and Disease · doi:10.14336/ad.2013.0400295 · Cited by 277
Replication and reproducibility in spinal cord injury research
Steward, O., Popovich, P. G., Dietrich, W. D., & Kleitman, N. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.06.017 · Cited by 186
Leung, V., Rousseau-Blass, F., Beauchamp, G., & Pang, D. S. J. (2018) · PLOS ONE · doi:10.1371/journal.pone.0197882 · Cited by 172
Apolloni, S., Amadio, S., Montilli, C., Volonte, C., & D'Ambrosi, N. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt259 · Cited by 109
Modeling cell-autonomous motor neuron phenotypes in ALS using iPSCs
Hawrot, J., Imhof, S., & Wainger, B. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104680 · Cited by 74
Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis
Potenza, R. L., De Simone, R., Armida, M., Mazziotti, V., Pèzzola, A., Popoli, P., & Minghetti, L. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0462-2 · Cited by 69
Schulz, J. B., Cookson, M. R., & Hausmann, L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13844 · Cited by 52
T 2 -Weighted MRI Detects Presymptomatic Pathology in the SOD1 Mouse Model of ALS
Evans, M. C., Serres, S., Khrapitchev, A. A., Stolp, H. B., Anthony, D. C., Talbot, K., Turner, M. R., & Sibson, N. R. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.19 · Cited by 37
Li, X., Dong, L., Li, A., Yi, J., Brotto, M., & Zhou, J. (2022) · Biomolecules · doi:10.3390/biom12020333 · Cited by 33
ROCK inhibition improves axonal regeneration in a preclinical model of amyotrophic lateral sclerosis
Joshi, A. R., Muke, I., Bobylev, I., & Lehmann, H. C. (2019) · Journal of Comparative Neurology · doi:10.1002/cne.24679 · Cited by 27
“We chose this timepoint since it more closely replicates the situation in humans in which diagnosis and subsequent treatment does not occur before the later stages of the disease (Ludolph et al., 2010).”
MethodEffects of RAGE inhibition on the progression of the disease in hSOD1G93A ALS mice
Liu, L., Killoy, K. M., Vargas, M. R., Yamamoto, Y., & Pehar, M. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.636 · Cited by 17
Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis
Ryu, I. S., Ha, D.-I., Jung, Y.-J., Lee, H. J., Kim, I., Lim, Y. N., Min, H. S., Kim, S. H., Yoon, I., Cho, H.-J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020615 · Cited by 2
“Specifically, we analyzed miR-485-3p expression in spinal cord tissues at early and late stages of disease in both WT and SOD1 G93A transgenic mice, as these regions are critically implicated in the pathophysiology of ALS [27–29].”
Metadata
- Authors
- Ludolph, A. C., Bendotti, C., Blaugrund, E., Chio, A., Greensmith, L., Loeffler, J.-P., Mead, R., Niessen, H. G., Petri, S., Pradat, P.-F., Robberecht, W., Ruegg, M., Schwalenstöcker, B., Stiller, D., van den Berg, L., Vieira, F., & von Horsten, S.
- Venue
- Amyotrophic Lateral Sclerosis
- Publisher
- Informa UK Limited
- Published
- 2010-01
- Volume
- 11
- Issue
- 1-2
- Pages
- 38-45
- ISSN
- 1471-180X (ISSN-L)
- 1748-2968
- OpenAlex
- W2083040497
- Cited by
- 315
- References
- 19
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.